Biopharmaceutical company focused on discovering and developing drugs against aging disorders and cancer.
Founded in 2018, Atropos is a biotechnology platform company focused on the discovery, development, and commercialization of therapies targeting the formation of senescent cells. The company leverages unexploited insights in senescence biology to discover agents and modalities. This disruptive approach to "aging" disorders targets that which is common to these diseases, the stress-induced accumulation of the senescent cell in various tissues.
Visit website: https://www.atroposthera.com/
People at Atropos Therapeutics
Professor at Memorial Sloan-Kettering Cancer Center and founder of Atropos Therapeutics.
Atropos Therapeutics News
LMC provides background and success outlook on 14 leading senolytic companies
Longevity Marketcap - 15-Dec-2020
Comprehensive review of companies' clinical and financial state of playRead more...
Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...Read more...